I'm sure @EliLillyandCo will continue to grow, but the gain-potential of such a large company ($LLY) is much smaller than that of @AbCelleraBio ($ABCL). Market caps: $1.36 trillion (LLY) vs $0.0038 trillion (ABCL) This is the difference of a couple of orders of magnitude (357x difference). If we consider today as the baseline market cap for our comparison going forward, it seems unlikely that LLY sees the same gains as ABCL. My educated guess is ABCL will *vastly* outpace LLY (on a percentage-growth basis) from here on out. It won't even be close. Come back to this in 5 years and see. I am betting on it with my wallet. ABCL just advanced 3 new molecules (ABCL992, ABCL385, and ABCL646) into the final preparation stage before human testing, on top of their already best-in-class ABCL635 Phase 2 results. This makes a total of 6 programs, with more being added every year. The future is very bright for ABCL, with its superior tech stack and visionary leadership. Once they successfully tackle some oncology targets (could take a few years), watch the market cap soar. I currently have 18% of my portfolio allocated to ABCL and I would like to get that to 25%. It's the only non-crypto that I hold, and that's saying something in itself for someone who rarely buys stocks. @JackPrescottX @tyler_bosserman @Spanos9118 @jinseongeo83473
𝙲𝚘𝚕𝚒𝚗 𝚃𝚊𝚕𝚔𝚜 𝙲𝚛𝚢𝚙𝚝𝚘Share

Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.